ABBV vs PLX

AbbVie Inc. (ABBV) is a well-established mega-cap pharmaceutical company with a robust product portfolio, strong financial health, and a leading position in key therapeutic areas. It excels as a stable dividend payer and a defensive holding. However, its fundamental characteristics, including its immense market capitalization ($397.29B), the mature nature of the pharmaceutical industry, high R&D c...

Protalix (PLX) maintains significant growth potential following the EU approval of Elfabrio's expanded dosing regimen and the triggered $25.0 million milestone, boosting projected cash to ~$50 million by April 2026. This, coupled with robust 2026 revenue guidance of $78–$83 million, strengthens its strategic market position in rare diseases. However, the FY 2025 TTM net loss of $6.6 million, a cle...